Skip to content

Clinical research of liposmal albendazole for treating echinococcosis

Clinical effect and safety of liposomal albendazole and tablet- albendazole for the treatment of human cystic echinococcosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNRC-11001329
Enrollment
Unknown
Registered
2011-04-20
Start date
2008-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Echinococcosis

Interventions

Group A:Tablet-albendazole
Group B:Liposomal albendazole

Sponsors

First Teaching Hospital, Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age from 14 to 70, Male or Female, all nations; 2. Diagnostic standard as follows: B ultrasound or X ray or CT scan confirmed patients with echinococcosis; typing of echinococcosis are confirmed by check of image as following: simple cyst(CE1) or multiple daughter cyst(CE2), or cyst with detachment of laminated membrane (CE3); patients as volunteers would like receive medical treatment at least 6 months; patients with different type of echinococcosis not want to do surgery and want accept chemotherapy after several operations; fast diagnostic kit for echinococcosis could be auxiliary diagnistic sdandard.

Exclusion criteria

Exclusion criteria: 1. Patients with cystic echinococcosis which had being necrotic and/or solid (typing CE4 and CE5); 2. Patients with serious dysfunction of single organ and/or multi-organs; pregnant woman or female are in lactation period; 3. Patients do not want accept chemotherapy.

Design outcomes

Primary

MeasureTime frame
Effective rate, curtive rate;

Countries

China

Contacts

Public ContactHaitao Li
lht45182@yahoo.com.cn+86 13899812351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026